急性髓系白血病(AML)是一种异质性血液肿瘤,免疫治疗效果较差。这项研究旨在开发单核细胞/巨噬细胞相关的预后风险评分(MMrisk)并确定AML的新治疗性生物标志物。我们利用差异表达基因(DEGs)结合单细胞RNA测序来鉴定单核细胞/巨噬细胞相关基因(MMGs)。使用单变量Cox回归分析和LASSO回归分析选择了八个基因用于MM风险模型的构建。然后,我们在两个GEO数据集上验证了MMrisk。最后,我们调查了免疫疗法的免疫学特征和优势,以及针对MM危险人群的潜在靶向药物.我们的研究发现,MMrisk由8个MMG组成,包括HOPX,CSTB,MAP3K1,LGALS1,CFD,MXD1、CASP1和BCL2A1。低MM风险组存活时间长于高MM风险组(P<0.001)。高MM组与B细胞呈正相关,浆细胞,CD4记忆细胞,肥大细胞,CAF,单核细胞,M2巨噬细胞,内皮,肿瘤突变,和大多数免疫检查点(PD1,Tim-3,CTLA4,LAG3)。此外,药物敏感性分析显示AZD.2281、阿西替尼、AUY922,ABT.888和ATRA对高危MM患者有效。我们的研究表明,MMrisk是一种潜在的生物标志物,有助于识别AML免疫学的分子特征。
Acute myeloid leukemia (AML) is a heterogeneous hematological tumor with poor immunotherapy effect. This study was to develop a monocyte/macrophage-related prognostic risk score (MMrisk) and identify new therapeutic biomarkers for AML. We utilized differentially expressed genes (DEGs) in combination with single-cell RNA sequencing to identify monocyte/macrophage-related genes (MMGs). Eight genes were selected for the construction of a MMrisk model using univariate Cox regression analysis and LASSO regression analysis. We then validated the MMrisk on two GEO datasets. Lastly, we investigated the immunologic characteristics and advantages of immunotherapy and potential targeted drugs for MMrisk groups. Our study identified that the MMrisk is composed of eight MMGs, including HOPX, CSTB, MAP3K1, LGALS1, CFD, MXD1, CASP1 and BCL2A1. The low MMrisk group survived longer than high MMrisk group (P < 0.001). The high MMrisk group was positively correlated with B cells, plasma cells, CD4 memory cells, Mast cells, CAFs, monocytes, M2 macrophages, Endothelial, tumor mutation, and most immune checkpoints (PD1, Tim-3, CTLA4, LAG3). Furthermore, drug sensitivity analysis showed that AZD.2281, Axitinib, AUY922, ABT.888, and ATRA were effective in high-risk MM patients. Our research shows that MMrisk is a potential biomarker which is helpful to identify the molecular characteristics of AML immunology.